Product Description
AstraZeneca is developing TACE (transarterial chemoembolization) as a transarterial therapy procedure for the treatment of hepatocellular carcinoma (HCC). (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03778957)
Mechanisms of Action: ER Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral, Injection
FDA Designation: *
Approval Status: Approved
Approved Countries: Brazil | Chile | Colombia | Dominican Republic | Ecuador | India | Ireland | Ukraine
Approved Indications: None
Known Adverse Events: None
Company: Zhejiang University
Company Location: Asia Pacific
Company Founding Year: 1897
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, France, Germany, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Malaysia, Mexico, Netherlands, New Zealand, Norway, Philippines, Poland, Portugal, Puerto Rico, Russia, Saudi Arabia, Singapore, South Korea, Spain, Taiwan, Thailand, Ukraine, United Kingdom, United States, Unknown Location, Vietnam
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Hepatocellular Carcinoma|Lewy Body Disease|Liver Cancer|Parkinson's Disease
Phase 2: Neuroendocrine Tumors
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03143270 |
NCT03143270 | P1 |
Active, not recruiting |
Liver Cancer |
2026-04-01 |
50% |
2025-05-03 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT02724540 |
UPCC 01215 | P2 |
Completed |
Neuroendocrine Tumors |
2024-04-30 |
19% |
2025-01-07 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT05301842 |
EMERALD-3 | P3 |
Active, not recruiting |
Hepatocellular Carcinoma |
2025-12-31 |
77% |
2025-01-16 |
|
NCT04246177 |
LEAP-012 | P3 |
Active, not recruiting |
Lewy Body Disease|Hepatocellular Carcinoma|Parkinson's Disease |
2025-08-19 |
41% |
2025-12-18 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT05970666 |
23-OBU-FJ-HCC-II-012 | P2 |
Recruiting |
Hepatocellular Carcinoma |
2026-11-15 |
42% |
2024-02-29 |
Primary Endpoints|Treatments|Trial Status |
NCT05171335 |
PRO00028690 | P2 |
Enrolling by invitation |
Hepatocellular Carcinoma |
2026-06-30 |
63% |
2022-09-22 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
NCT04472767 |
UCI 19-49 [HS# 2020-5807] | P2 |
Recruiting |
Hepatocellular Carcinoma |
2026-06-01 |
12% |
2024-03-06 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT06114082 |
IDADOX | P2 |
Recruiting |
Hepatocellular Carcinoma|Liver Cancer |
2025-12-31 |
12% |
2025-01-08 |
Primary Completion Date|Primary Endpoints |
NCT05319431 |
AK104-216 | P2 |
Active, not recruiting |
Hepatocellular Carcinoma |
2023-08-15 |
12% |
2025-03-13 |
Primary Completion Date|Primary Endpoints|Treatments|Trial Status |
NCT03397654 |
PETAL | P2 |
Completed |
Hepatocellular Carcinoma |
2023-02-01 |
12% |
2025-02-04 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT04340193 |
CheckMate 74W | P3 |
Completed |
Liver Cancer |
2023-12-12 |
70% |
2024-11-27 |
|
NCT03778957 |
EMERALD-1 | P3 |
Active, not recruiting |
Hepatocellular Carcinoma |
2023-09-11 |
83% |
2024-01-18 |
Primary Endpoints|Study Completion Date|Treatments |
jRCT2080225190 |
jRCT2080225190 | P3 |
Completed |
Hepatocellular Carcinoma |
2029-12-31 |
|||
JapicCTI-205286 |
JapicCTI-205286 | P3 |
Active |
Hepatocellular Carcinoma |
2029-12-31 |
|||
NCT04712643 |
ML42612 | P3 |
Active, not recruiting |
Hepatocellular Carcinoma |
2029-02-01 |
86% |
2025-02-06 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT05320692 |
SHR-1210-â ¢-336 | P3 |
Active, not recruiting |
Hepatocellular Carcinoma |
2026-07-30 |
52% |
2025-12-12 |
|
NCT05613478 |
2022-SR-558 | P3 |
Recruiting |
Hepatocellular Carcinoma |
2025-11-01 |
12% |
2025-01-03 |
|
NCT06882876 |
JS014-F01 | P1 |
Enrolling by invitation |
Hepatocellular Carcinoma |
2027-01-01 |
2025-09-20 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT06371157 |
AK104-308 | P3 |
Recruiting |
Hepatocellular Carcinoma |
2025-10-25 |
41% |
2025-03-13 |
Primary Endpoints |
NCT06995105 |
CISLD-13 | P2 |
Recruiting |
Hepatocellular Carcinoma |
2027-04-01 |
12% |
2025-05-31 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/03/2026 |
News Article |
PreciseOnco research consortium awarded EUR 14.9 million IHI grant to drive breakthroughs in precision cancer treatment |
|
11/18/2025 |
News Article |
TriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery™ |
|
11/11/2025 |
News Article |
Interventional Oncology Market to Reach $4.38 Billion by 2030 at CAGR 8.55% - Grand View Research, Inc. |
|
11/10/2025 |
News Article |
Booking Health Announces Expanded Access to Stage 4 Lung Cancer Treatments During Lung Cancer Awareness Month |